This study examined the real-life outcomes of apremilast in patients with psoriasis (selective phosphodiesterase-4 inhibitor) in routine practice.
This
longitudinal study comprising 159 patients with psoriasis and psoriatic
arthritis showed apremilast to be an effective and safe therapy for improving
skin condition and lower psoriasis severity.
During
the course of 12 months, noticeable improvement in Dermatology Life Quality
Index scores, body surface area, and Psoriasis Area and Severity Index was
observed. However, there were no changes in improvement considering the body
mass index (BMI). Lack of response led to the withdrawal of apremilast in 10.6%
of the patients.
Apremilast
is a safe and effective therapy in psoriatic patients, and its outcome is not
dependent on the BMI.
Acta dermato-venereologica
Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study
Giovanna Malara et al.
Comments (0)